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Superparamagnetic iron oxide (SPIO)-based colloid has been used clinically as a tissue-specific magnetic resonance contrast agent.
We coupled monoclonal antibody A7 (Mab A7), which reacts specifically with human colorectal carcinoma, to Ferumoxides (SPIO)
and examined the accumulation of this conjugate in xenografted tumours in nude mice. We examined in vitro immunoreactivity of
Mab A7 coupled to Ferumoxides and its in vivo distribution in nude mice with human colorectal carcinoma. Magnetic resonance
imaging of tumour-bearing nude mice was performed 72h after injection of A7-Ferumoxides. A7-Ferumoxides retained binding
activities that were nearly identical to intact Mab A7. More of the radiolabelled A7-Ferumoxides accumulated in the tumour than
normal mouse IgG-Ferumoxides from 12h onwards after injection (Po0.05). Both A7-Ferumoxides and normal mouse IgG-
Ferumoxides disappeared from blood linearly over time. The accumulation levels in normal tissue decreased linearly over time but
were lower than levels in tumours from 6h. In magnetic resonance T2-weighted imaging of the tumour-bearing nude mice, signal
intensity was reduced at the margin of the tumour by injection of A7-Ferumoxides. Mab A7 coupled to Ferumoxides is potentially
suitable as a magnetic resonance contrast agent for detecting local recurrence of rectal carcinoma.
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As chemotherapy, radiotherapy, and thermotherapy adjuncts to
surgical treatment are performed for rectal carcinoma, the survival
rate has improved in recent years (Hildebrandt et al, 2000; Adell
et al, 2001; Frykholm et al, 2001). Total mesorectal excision for
rectal cancer has reduced the rate of local recurrence and raised
overall survival. Yet, local recurrence, which is the most common
pattern in rectal carcinoma, occurs in approximately 8–15% of
patients even after curative surgery (Goldberg and Nicholls, 1995;
Wibe et al, 2003). Moreover, a diagnostic problem is represented
by the difficult differentiation of local recurrence from post-
operative fibrosis by either computed tomography (CT) or
magnetic resonance (MR) imaging (Balzer et al, 2003). The
development of contrast agents which accumulate in rectal
carcinoma might eventually improve its prognosis.
Although MR imaging currently is considered the most accu-
rate method for diagnosing local recurrence, unenhanced and
gadolinium-enhanced MR imaging are not sensitive enough
for differentiation between local recurrence and other tissues.
Magnetic resonance imaging techniques have been proposed,
including the use of ferromagnetic particles (Fe3O4) as MR contrast
agents (Mendonca-Diasand and Lauterbur, 1986; Renshaw et al,
1986a,b). Superparamagnetic iron oxide (SPIO)-based colloid has
been investigated as an MR contrast agent (Weissleder et al,
1987a,b). Ferumoxides, one SPIO-based colloid, has been used
clinically as a tissue-specific MR contrast agent in order to
distinguish liver tumours (Clement et al, 1991). No MR contrast
agent has been shown to detect the local recurrence of rectal
carcinoma.
We have previously reported that monoclonal antibody A7 (Mab
A7), produced from human colonic carcinoma, reacts immuno-
histochemically with colorectal carcinomas with high sensitivity
(Otsuji et al, 1992; Takahashi et al, 1993). In this study, we coupled
Mab A7 to Ferumoxides in order to examine whether the complex
would be useful as an MR contrast agent for local recurrence of
rectal carcinoma.
MATERIALS AND METHODS
Cell line
WiDr, the human colonic carcinoma cell line, was used in this
study. WiDr cells were incubated in RPM1 1640 media supple-
mented with 10% foetal bovine serum (FBS) in an atmosphere of
5% CO2 and air at 371C.
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Cultured WiDr cells were harvested by ethylenediamine tetra-
acetic acid (EDTA) treatment, washed, and resuspended in PBS.
Approximately 10
7 viable cells were injected subcutaneously into
the backs of athymic 8-week-old nude mice (BALB/C-nu/nu, male,
mean body weight: approximately 25g) (Shimizu, Shizuoka,
Japan). A tumour mass was detected in all mice injected with
WiDr cells 14 days after inoculation.
Monoclonal antibody A7
Monoclonal antibody A7 was produced from spleen cells of a
mouse immunised against human colonic adenocarcinoma, Colon
6 (Kotanagi et al, 1986). Monoclonal antibody A7 belongs to the
IgG1 subclass and recognises a 42000Da glycoprotein on the cell
surface. It has been reported to react with more than 70% of
human colorectal carcinoma cell lines (Takahashi et al, 1993), but
it does not react immunohistochemically with normal tissues.
Normal mouse IgG was purchased from Sigma-Aldrich (St Louis,
MO, USA).
Preparation of radiolabelled Mab
Radiolabelling of Mab A7 with
125I (Amersham Japan, Tokyo) was
performed by the chloramine-T method (Hunter and Greenwood,
1962). The iodinated Mab A7 was separated from excess reactants
by passage through a Sephadex G-25 column. Monoclonal
antibody A7 was labelled with
125I to specific activities of
5.0mCimg
1. As a control, normal mouse IgG also was labelled
with
125I by a similar method.
Preparation of SPIO
Ferumoxides, a SPIO - based colloid, was obtained from Advanced
Magnetics Co. (Cambridge, MA, USA). Ferumoxides is a colloid of
SPIO (FeO and Fe2O3) supported with dextran T-10, and the mean
diameter of particles is approximately 100nm. It contained
11.2mgFeml
1.
Mab A7 coupled to Ferumoxides
Monoclonal antibody A7 was coupled with the dextran of
Ferumoxides using a modification of the sodium periodate method
(Molday and Mackenzie, 1982). In all, 1ml of Ferumoxides was
added to 10mM sodium periodate. The dextran of Ferumoxides
was partially oxidised. The reaction was carried out for 60min at
room temperature with stirring, the oxidised Ferumoxides was
separated from residual periodate by passage through a Sephadex
G-25 column. Then 3mg of Mab A7 was added to the solution of
oxidised Ferumoxides. The aldehyde functions of oxidised dextran
react with the amino sites of Mab A7 to form Schiff bases. The
conjugation reaction was carried out for 24h at room temperature
with stirring, 0.5ml of 1% sodium borohydride solution was then
added in order to reduce the product to secondary amine linkages.
After 15min, the reaction was terminated by dialysing against
0.1 M sodium phosphate buffer. Ferumoxides coupled to antibody
was separated from unconjugated antibody by centrifugation for
15min at 15000rpm. The supernatant was discarded, and the
pellet containing the A7-Ferumoxides complex was resuspended.
Similarly, Ferumoxides was coupled to normal mouse IgG as a
control. Approximately 20% of the initially added antibody was
coupled with Ferumoxides.
Stability of A7-Ferumoxides in human serum
125I-labelled A7-Ferumoxides (0.5mg) was added to volunteer
human serum (0.5ml), and the serum was allowed to clot in
humidified CO2 (371C, 5% CO2 atmosphere). At 24, 72, and 120h
after incubation,
125I-labelled A7-Ferumoxides was separated from
unconjugated antibody by centrifugation for 15min at 15000rpm.
Radioactivities of 100m1 of each supernatant were counted with a
gamma scintillation counter (COBRA 5002/5003, Packard, CO,
USA) and were compared with the count of the supernatant of the
sample prior to incubation.
In vitro binding activities of A7-Ferumoxides to WiDr cells
The binding activities of A7-Ferumoxides were examined by a
competitive inhibition radioimmunoassay in WiDr cells. Aliquots
of WiDr cells (10
6) were incubated with a fixed quantity of
125I-
labelled A7 (10
5 cpm) in the presence of serially four-fold diluted
A7-Ferumoxides or intact A7 at 371C for 60min. The concentra-
tion of A7-Ferumoxides and intact A7 ranged from 10.04
6 to
10.0mgml
1. As a control, normal mouse IgG-Ferumoxides was
used instead of A7-Ferumoxides or intact A7. After incubation, the
cells were washed three times with PBS. Radioactivity of the cell
pellets was counted with a gamma scintillation counter (COBRA
5002/5003, Packard), and the percent inhibition was calculated
compared to the results of only
l25I-labelled A7.
Biodistribution of
l25I-labelled A7-Ferumoxides in nude
mice bearing human colorectal carcinoma xenografts
The biodistribution of
125I-labelled A7-Ferumoxides was examined
in nude mice bearing WiDr tumours. At 14 days after inoculation,
48 tumour-bearing nude mice were divided into two groups: 24
mice in one group were injected intravenously with 1.0mCi of
125I-labelled A7-Ferumoxides via the tail vein, 24 mice in another
group were injected with 1.0mCi of
125I-labelled normal mouse
IgG-Ferumoxides. Three mice from each group were killed and
dissected at 2, 6, 12, 24, 48, 72, 96 and 120h after injection. After
dissection, the tumours, blood, and normal organs (lung, heart,
liver, spleen, pancreas, stomach, colon, and kidney) were weighed.
The mean weight of the tumours was 178mg. The radioactivity in
each tissue was counted with a gamma scintillation counter. The
results are expressed as the percentage of the injected dose g
1
(%IDg
1). Furthermore, to compare the kinetics of the two probes
in the tumour, blood, and normal tissues, the tissue/blood ratios
of the radioactivity per unit weight were calculated from these
data. Student’s t-test was used to determine statistically significant
differences which were set at Po0.05. Care of the animals and the
experimental procedures were carried out in accordance with the
guideline of the United Kingdom Co-ordinating Committee on
Cancer Research (UKCCCR, 1998).
MR imaging of nude mice bearing human colorectal
carcinoma xenografts
A WiDr tumour-bearing nude mouse was studied under pento-
barbital anaesthesia 72h after injection of A7-Ferumoxides. All MR
images were obtained with a 1.5T clinical scanner with a small
field of view (FOV) coil (Eclipse 1.5T, Marconi Medical systems,
UK). These images were obtained with a gradient echo sequence,
so-called ‘T2*’. We used T2* sequences to visualise the uptake of
SPIO because the T2* sequence was the most sensitive at
visualising the magnetic susceptibility. A tumour-bearing nude
mouse injected with IgG-ferumoxides was imaged at the same
time.
RESULTS
Stability of A7-Ferumoxides in human serum
Radioactivities of each supernatant at 24, 72, and 120h after
incubation of
125I-labelled A7-Ferumoxides with human serum
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before incubation.
In vitro binding activities of A7-Ferumoxides to WiDr cells
The binding activities of A7-Ferumoxides were compared with
those of intact Mab A7 by a competitive inhibition radio-
immunoassay in WiDr cells. Mab A7-Ferumoxides retained
binding activities which were nearly identical to intact Mab A7
(Figure 1). Normal mouse IgG-Ferumoxides did not react with
WiDr cells.
Biodistribution of
l25I-labelled A7-Ferumoxides in nude
mice bearing human colorectal carcinoma xenografts
Significantly larger amounts of the
125I-labelled A7-Ferumoxides
accumulated in the tumour than
125I-labelled normal mouse
IgG-Ferumoxides from 12 to 120h after injection (Po0.05).
(Figure 2). The tumour accumulation level of
125I-labelled
A7-Ferumoxides increased gradually, and radioactivity reached
9.8772.96% IDg
1 24h after injection and then decreased
slowly. By contrast, the tumour accumulation level of
125I-labelled
normal mouse IgG-Ferumoxides decreased after radioactivity
reached only 3.7670.48% IDg
1 at 12h after injection.
125I-labelled A7-Ferumoxides and
125I-labelled normal mouse
IgG-Ferumoxides disappeared from blood linearly over time with
similar clearance curves (Figure 3). As for all resected normal
tissues, the accumulation levels of
125I-labelled A7-Ferumoxides
decreased linearly over time and were lower than those for
tumours from 6h onwards after injection (Figure 4A–H).
Accumulations of
125I-labelled A7-Ferumoxides and
125I-labelled
normal mouse IgG-Ferumoxides were similar in normal tissues. To
examine the specific localisation of
125I-labelled A7-Ferumoxides
and
125I-labelled normal mouse IgG-Ferumoxides in tumours, the
ratio of radioactivity in tumour and normal tissues to blood
was determined. The tumour/blood ratio of the
125I-labelled A7-
Ferumoxides increased in a time-dependent manner to 2.2370.48
at 72h after injection. By contrast, the tumour/blood ratio of
125I-
labelled normal mouse IgG-Ferumoxides was lower than that of
125I-labelled A7-Ferumoxides (Figure 5).
MR imaging of human nude mice bearing human
colorectal carcinoma xenografts
As shown in Figure 6, the signal intensity of MR T2-weighted
imaging was reduced at the margin of tumours in a A7-
Ferumoxides-injected mouse. By contrast, there was no change
in intensity in tumours of a normal mouse IgG-Ferumoxides-
injected mouse.
DISCUSSION
Computed tomography and MR imaging are used currently for
diagnosing postoperative local recurrence of rectal carcinoma.
Although MR imaging is more successful than CT in the
differentiation of local recurrence from postoperative fibrosis
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Figure 1 The binding activities of A7-Ferumoxides were compared with
those of intact A7 by competitive radioimmunoassay in WiDr cells. A7-
Femmoxides retained binding activities nearly identical to intact A7. Normal
mouse IgG-Ferumoxides had no antigen-binding activity in WiDr cells. J,
A7-Ferumoxides; n, intact A7; K, normal mouse IgG-Ferumoxides.
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Figure 2 The accumulation of
125I-labelled A7-Ferumoxides and
125I-
labelled normal mouse IgG-Ferumoxides in WiDr tumours of mice after
intravenous injection. A significantly larger amount of
125I-labelled A7-
Ferumoxides accumulated in the tumour than
125I-labelled normal mouse
IgG-Ferumoxides from 12 to 120h after injection (Po0.05). The tumour
accumulation of
125I-labelled A7-Ferumoxides increased up to 48h and
then decreased slowly. J, A7-Ferumoxides; K, normal mouse IgG-
Ferumoxides; points, means; bars, s.d.
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Figure 3 Blood concentrations of
125I-labelled A7-Ferumoxides and
125I-
labelled normal mouse IgG-Ferumoxides in mice that received an
intravenous injection.
125I-labelled A7-Ferumoxides and
125I-labelled
normal mouse IgG-Ferumoxides disappeared from blood linearly over
time, with similar clearance curves. J, A7-Ferumoxides; K, normal mouse
IgG-Ferumoxides; points, means; bars, s.d.
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(Krestin et al, 1988), the diagnosis of local recurrence at early
stages is often difficult. In many cases, tumours already have
enlarged and invaded adjacent organs by the time of detection.
Improvement of the prognosis might be expected from earlier
diagnosis.
Recently, the clinical value of advanced imaging techniques for
differentiation between local recurrence and other tissues has been
evaluated. Positron emission tomography (PET) can complement
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Figure 4 A to H. The accumulation of
125I-labelled A7-Ferumoxides and
125I-labelled normal mouse IgG-Ferumoxides in normal tissues of mice after
intravenous injection. The accumulation of
125I-labelled A7-Ferumoxides and
125I-labelled normal mouse IgG-Ferumoxides was similar in normal tissues. J,
A7-Ferumoxides; K, normal mouse IgG-Ferumoxides; points, means; bars, s.d.
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Figure 5 Tumour/blood radioactivity ratio of
125I-labelled A7-Ferum-
oxides and
125I-labelled normal mouse IgG-Ferumoxides in mice after
intravenous injection. The tumour/blood radioactivity ratio of the
125I-
labelled A7-Ferumoxides increased rapidly with time. J, A7-Ferumoxides;
K, normal mouse IgG-Ferumoxides; points, means; bars, s.d.
IgG-Ferumoxides A7-Ferumoxides
Figure 6 The signal intensity of MR T2-weighted imaging was reduced at
the margin of tumours in an A7-Ferumoxides-injected mouse. By contrast,
there was no change in intensity in tumours of a control IgG-Ferumoxides-
injected mouse.
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tumour and postoperative scar (Ito et al, 1992; Takeuchi et al,
1999). The values of CEA scintigraphy and dynamic MR imaging
have also been evaluated (Muller-Schimpfle et al, 1993; Blomqvist
et al, 1996; Jarv et al, 2000; Torricelli et al, 2003).
In the field of MR contrast agents, the usefulness of
ferromagnetic colloidal particles coated with methacrylate copo-
lymers coupled to antibodies has been reported (Renshaw et al,
1986a). Superparamagnetic iron oxide-based colloids as tissue-
specific contrast agents have been developed. Superparamagnetic
iron oxide produces dephased adjacent protons with loss of signal
intensity in specific organs at low doses. Superparamagnetic iron
oxide is magnetised within an external magnetic field and loses
magnetisation without an external magnetic field. It disturbs a
local magnetic field and shortens the transverse relaxation time.
Ferumoxides and Ferucarbotran, which are SPIO-based colloids,
are used clinically as liver-targeted MR contrast agents. They are
trapped in phagocytic cells of the reticuloendothelial system and
reduce the signal intensity of normal liver tissue in T2-weighted
pulse sequences. As the signal intensity of the liver tumour without
the reticuloendothelial system does not change, the contrast
between liver tumours and normal liver tissues is improved.
However, a contrast agent that is useful for local recurrence of
rectal carcinoma has not been developed. We considered that
development of an MR contrast agent that accumulates specifically
in rectal carcinoma could make detection of local recurrence easier
and lead to improvement of curability. We examined whether Mab
A7 is applicable to an MR contrast agent for local recurrence of
rectal carcinoma.
We have previously coupled Mab A7 with ferromagnetic
particles (Bio-Mag4100) and reported its usefulness in rectal
carcinoma (Kotani, 1995). However, it disappeared from the blood
relatively slowly, and the tumour to blood ratio was not high
enough to distinguish recurrent tumour reliably by MR imaging
of patients (unpublished data). If SPIO is carried into tumour
by monoclonal antibody, it is useful as an MR contrast agent for
detection. We successfully coupled Mab A7 with Ferumoxides, and
the immunoreactivity of the complex was retained. A7-Ferum-
oxides was stable in human serum for at least 5 days. Larger
amounts of the complex accumulated in tumour than did normal
mouse IgG-Ferumoxides. Furthermore, a larger amount of
125I-
labelled A7-Ferumoxides accumulated in the tumour than in either
blood or normal tissues. A7-Ferumoxides accumulated specifically
in the tumour by antigen-antibody-specific binding. A7-Ferum-
oxides may therefore accumulate in recurrent tumours if
administered to patients with local recurrence of rectal carcinoma.
In MR imaging of nude mice bearing human colorectal carcinoma,
the signal intensity was reduced at the margin of the tumour by
injection of A7-Ferumoxides. The reason for the heterogeneity of
localisation of A7-Ferumoxides in tumour may be explained by
differences in blood supply within the tumour. In a previous study
using
131I-labelled Mab A7, more antibody was localised at the
margin than at the centre of a WiDr tumour by radioautography
(unpublished data).
From these results, we conclude that Mab A7 coupled to
Ferumoxides is potentially useful as an MR contrast agent for local
recurrence of human rectal carcinoma.
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